Pluronic polymer functionalized polymeric nanoparticles loaded capecitabine and thymoquinone for targeting colorectal cancer an experimental study

Abstract

Colorectal cancer (CRC), often known as colon cancer, typically originates as a benign polyp in the colon or rectum and spreads slowly over 10–20 years. About 9.4% of cancer-related deaths in 2020 were caused by CRC. Survival rates from CRC are significantly affected by both recurrence and metastasis. In systemic therapy, the problem of non-targeted drug dispersion is of paramount importance. The main worries and key grounds for chemotherapy failure are side effects and resistance to medicines, both of which are caused by this lack of specificity. To tackle these challenges, polymeric nanoparticles (PNP) were developed as transporter devices for CRC therapy, with the ability to encapsulate diverse medications, shield therapeutic molecules, and give numerous advantages above their counterparts in bulk. To the extent of our information this is the first work to demonstrate that functionalized Polymeric nanoparticle loaded CAP and TQ can effectively be used as a synergistic combination to induce apoptosis, which could be used to kill off cancer cells. Aim This research aims to formulate a Nano-based drug delivery system targeting colorectal cancer. The objectives of the study are: 1. To formulate, optimize, and evaluate pluronic polymer functionalized nanocarrier system loaded Capecitabine and Thymoquinone. 2. To assess the anticancer activity of optimized formulation by conducting in vitro and in vivo studies.